HIGHLY WATER-SOLUBLE SALTS OF A SHORT-ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREBY

DE602016095585T2Active Publication Date: 2026-06-03MILESTONE PHARMA INC

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
MILESTONE PHARMA INC
Filing Date
2016-04-13
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Current therapeutic modalities for cardiac arrhythmias, such as PSVT, are invasive or inefficient, and existing calcium channel blockers do not provide immediate relief due to their pharmacokinetic profiles, which hinder rapid absorption and metabolism, leading to delayed symptom alleviation.

Method used

Development of highly water-soluble salts of calcium channel blockers, such as methanesulfonate salts, for nasal administration, allowing rapid delivery and metabolism of the active compound to terminate arrhythmia episodes.

Benefits of technology

The formulation enables rapid termination of cardiac arrhythmia episodes by achieving therapeutically effective plasma concentrations within minutes, thereby providing immediate relief without prolonged cardiac exposure or side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.